PubMed
Cerebrolysin for acute ischemic stroke (review)
Chen N, Yang M, Guo J, et al. Cochrane Database Syst Rev. 2017
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 63% · Mixed 20% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.01–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 58% said they felt similar to their last entry, 31% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 29 days · Based on 292 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 57% · Mixed 32% · Unfavorable overall 11%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.05 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 52% said they felt similar to their last entry, 37% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 14 days · Based on 133 repeat reporters
Published sources linked on the Cerebrolysin and SS-31 wiki pages.
PubMed
Chen N, Yang M, Guo J, et al. Cochrane Database Syst Rev. 2017
PubMed
Ziganshina LE, Abakumova T, Nurkhametova D, et al. The Cochrane database of systematic reviews. 2023
PubMed
Ziganshina LE, Abakumova T, Vernay L. The Cochrane database of systematic reviews. 2017
PubMed
Szeto HH. AAPS J. 2006
PubMed
Butler J, Khan MS, Anker SD, et al. Eur J Heart Fail. 2020
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Tung C, Varzideh F, Farroni E, et al. International journal of molecular sciences. 2025
PubMed
Szeto HH, Birk AV. Clinical pharmacology and therapeutics. 2014